- Home
- ZEO vs AKTX Comparison
ZEO vs AKTX Comparison
Compare ZEO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- AKTX
- Stock Information
- Founded
- ZEO 2005
- AKTX N/A
- Country
- ZEO United States
- AKTX United States
- Employees
- ZEO N/A
- AKTX N/A
- Industry
- ZEO
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- AKTX Health Care
- Exchange
- ZEO NYSE
- AKTX Nasdaq
- Market Cap
- ZEO 31.6M
- AKTX 24.5M
- IPO Year
- ZEO N/A
- AKTX N/A
- Fundamental
- Price
- ZEO $1.63
- AKTX $0.91
- Analyst Decision
- ZEO
- AKTX
- Analyst Count
- ZEO 0
- AKTX 0
- Target Price
- ZEO N/A
- AKTX N/A
- AVG Volume (30 Days)
- ZEO 20.8K
- AKTX 25.1K
- Earning Date
- ZEO 03-25-2025
- AKTX 03-25-2025
- Dividend Yield
- ZEO N/A
- AKTX N/A
- EPS Growth
- ZEO N/A
- AKTX N/A
- EPS
- ZEO N/A
- AKTX N/A
- Revenue
- ZEO $77,582,314.00
- AKTX N/A
- Revenue This Year
- ZEO N/A
- AKTX N/A
- Revenue Next Year
- ZEO N/A
- AKTX N/A
- P/E Ratio
- ZEO N/A
- AKTX N/A
- Revenue Growth
- ZEO N/A
- AKTX N/A
- 52 Week Low
- ZEO $1.05
- AKTX $0.85
- 52 Week High
- ZEO $8.90
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ZEO 33.69
- AKTX 41.35
- Support Level
- ZEO $1.56
- AKTX $0.89
- Resistance Level
- ZEO $1.71
- AKTX $1.00
- Average True Range (ATR)
- ZEO 0.13
- AKTX 0.09
- MACD
- ZEO -0.03
- AKTX 0.01
- Stochastic Oscillator
- ZEO 12.99
- AKTX 22.27
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).